Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry R Buller

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Thrombosis and Haemostasis|January 17, 2019
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY TrialAlexander T Cohen, Giancarlo Agnelli, Harry R Buller, et al.
The New England Journal of Medicine|December 11, 2012
Apixaban for extended treatment of venous thromboembolismGiancarlo Agnelli, Harry R Buller, Alexander Cohen, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|March 3, 2012
Paediatric anticoagulation guidelinesElise Schapkaitz, Gayle Gillian Sherman, Barry Frank Jacobson, et al.
Thrombosis Research|January 21, 2010
Active search for chronic thromboembolic pulmonary hypertension does not appear indicated after acute pulmonary embolismSulaiman Surie, Nadine S Gibson, Victor E A Gerdes, et al.
Thrombosis and Haemostasis|December 15, 2015
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trialGary E Raskob, Alex S Gallus, Paul Sanders, et al.
Thrombosis and Haemostasis|January 25, 2008
Further validation and simplification of the Wells clinical decision rule in pulmonary embolismNadine S Gibson, Maaike Sohne, Marieke J H A Kruip, et al.
Blood|July 16, 2008
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyHarry R Buller, Anthonie W A Lensing, Martin H Prins, et al.
The New England Journal of Medicine|September 15, 2007
Idraparinux versus standard therapy for venous thromboembolic disease, Harry R Buller, Ander T Cohen, et al.
The New England Journal of Medicine|September 15, 2007
Extended prophylaxis of venous thromboembolism with idraparinux, Harry R Buller, Ander T Cohen, et al.
Blood|June 17, 2006
A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutationMichiel Coppens, Marlene H van de Poel, Ivan Bank, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Thrombosis and Haemostasis|January 17, 2019
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY TrialAlexander T Cohen, Giancarlo Agnelli, Harry R Buller, et al.
The New England Journal of Medicine|December 11, 2012
Apixaban for extended treatment of venous thromboembolismGiancarlo Agnelli, Harry R Buller, Alexander Cohen, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|March 3, 2012
Paediatric anticoagulation guidelinesElise Schapkaitz, Gayle Gillian Sherman, Barry Frank Jacobson, et al.
Thrombosis Research|January 21, 2010
Active search for chronic thromboembolic pulmonary hypertension does not appear indicated after acute pulmonary embolismSulaiman Surie, Nadine S Gibson, Victor E A Gerdes, et al.
Thrombosis and Haemostasis|December 15, 2015
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trialGary E Raskob, Alex S Gallus, Paul Sanders, et al.
Thrombosis and Haemostasis|January 25, 2008
Further validation and simplification of the Wells clinical decision rule in pulmonary embolismNadine S Gibson, Maaike Sohne, Marieke J H A Kruip, et al.
Blood|July 16, 2008
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyHarry R Buller, Anthonie W A Lensing, Martin H Prins, et al.
The New England Journal of Medicine|September 15, 2007
Idraparinux versus standard therapy for venous thromboembolic disease, Harry R Buller, Ander T Cohen, et al.
The New England Journal of Medicine|September 15, 2007
Extended prophylaxis of venous thromboembolism with idraparinux, Harry R Buller, Ander T Cohen, et al.
Blood|June 17, 2006
A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutationMichiel Coppens, Marlene H van de Poel, Ivan Bank, et al.
Pageof 3